Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

References

• HoyerLWHemophilia AN Engl J Med1994330138478259143
   PubMed Web of Science ®Google Scholar
• CoppolaADi CapuaMDi MinnoMNTreatment of hemophilia: a review of current advances and ongoing issuesJ Blood Med2010118319522282697
   PubMedGoogle Scholar
• OrlovaNAKovnirSVVorobievIIGabibovAGVorobievAIBlood clotting factor VIII: from evolution to therapyActa Naturae201352193923819034
   PubMed Web of Science ®Google Scholar
• PipeSWNew therapies for hemophiliaHematology Am Soc Hematol Educ Program20162016165065627913542
   PubMed Web of Science ®Google Scholar
• PipeSWMontgomeryRRPrattKPLentingPJLillicrapDLife in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia ABlood2016128162007201627587878
   PubMed Web of Science ®Google Scholar
• ShapiroADLong-lasting recombinant factor VIII proteins for hemophilia AHematology Am Soc Hematol Educ Program20132013374324319160
   PubMed Web of Science ®Google Scholar
• Bensen-KennedyDBringing new therapy options to the hemophilia communityThromb Res2013131suppl 2S15S1823537722
   PubMed Web of Science ®Google Scholar
• MahlanguJKuliczkowskiKKarimFAEfficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia ABlood2016128563063727330001
   PubMed Web of Science ®Google Scholar
• Pabinger-FaschingIThe story of a unique molecule in hemophilia A: recombinant single-chain factor VIIIThromb Res2016141suppl 3S2S427288063
   PubMedGoogle Scholar
• ZollnerSRaquetEClaarPNon-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIIIThromb Res2014134112513124814969
   PubMed Web of Science ®Google Scholar
• ZollnerSBRaquetEMüller-CohrsJPreclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIIIThromb Res2013132228028723830969
   PubMed Web of Science ®Google Scholar
• MiaoHZSirachainanNPalmerLBioengineering of coagulation factor VIII for improved secretionBlood200410393412341914726380
   PubMed Web of Science ®Google Scholar
• SantagostinoEA new recombinant factor VIII: from genetics to clinical useDrug Des Devel Ther2014825072515
   PubMed Web of Science ®Google Scholar
• KavakliKYangRRusenLProphylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)J Thromb Haemost201513336036925546368
   PubMed Web of Science ®Google Scholar
• SandbergHKannichtCStenlundPFunctional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIIIThromb Res2012130580881723010293
   PubMed Web of Science ®Google Scholar
• ViuffDBarrowcliffeTSaugstrupTEzbanMLillicrapDInternational comparative field study of N8 evaluating factor VIII assay performanceHaemophilia201117469570221426445
   PubMed Web of Science ®Google Scholar
• KannichtCRamströmMKohlaGCharacterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIIIThromb Res20121311788823058466
   PubMed Web of Science ®Google Scholar
• TiedeABrandBFischerREnhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glyco-PEGylated recombinant factor VIII in patients with hemophilia AJ Thromb Haemost201311467067823398640
   PubMed Web of Science ®Google Scholar
• KaufmanRJPowellJSMolecular approaches for improved clotting factors for hemophiliaHematology Am Soc Hematol Educ Program20132013303624319159
   PubMed Web of Science ®Google Scholar
• ChowdaryPFosburyERiddellAMathiasMTherapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(R)) in hemophilia AJ Blood Med2016718719827695377
   PubMed Web of Science ®Google Scholar
• MahlanguJPowellJSRagniMVPhase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia ABlood2014123331732524227821
   PubMed Web of Science ®Google Scholar
• KlukowskaASzczepańskiTVdovinVKnaubSJansenMLiesnerRNovel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq(®)) in children with severe haemophilia A: efficacy, safety and pharmacokineticsHaemophilia Epub2015914
   Google Scholar
• SchmidbauerSWitzelRRobbelLPhysicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIIIThromb Res2015136238839526037285
   PubMed Web of Science ®Google Scholar
• SchulteSPioneering designs for recombinant coagulation factorsThromb Res2011128suppl 1S9S1222221848
   PubMed Web of Science ®Google Scholar
• DelignatSRepesséYNavarreteAMImmunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia AHaemophilia201118224825422044692
   PubMed Web of Science ®Google Scholar
• SorvilloNHartholtRBBloemEvon Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIIIHaematologica2016101330931826635035
   PubMed Web of Science ®Google Scholar
• BrandBGruppoRWynnTTEfficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patientsHaemophilia2016224e251e25827328112
   PubMed Web of Science ®Google Scholar
• WynnTTGumuscuBPotential role of a new PEGylated recombinant factor VIII for hemophilia AJ Blood Med2016712112827382347
   PubMed Web of Science ®Google Scholar
• ScharrerIBrayGLNeutzlingOIncidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma-derived factor VIII concentratesHaemophilia19995314515410444280
   PubMed Web of Science ®Google Scholar
• VielKRAmeriAAbshireTCInhibitors of factor VIII in black patients with hemophiliaN Engl J Med2009360161618162719369668
   PubMed Web of Science ®Google Scholar
• GunasekeraDEttingerRANakaya FletcherSFactor VIII gene variants and inhibitor risk in African American hemophilia A patientsBlood2015126789590425617427
   PubMed Web of Science ®Google Scholar
• MillerCHBensonJEllingsenDF8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicityHaemophilia201218337538222103590
   PubMed Web of Science ®Google Scholar
• GouwSCvan der BomJGLjungRFactor VIII products and inhibitor development in severe hemophilia AN Engl J Med2013368323123923323899
   PubMed Web of Science ®Google Scholar
• CalvezTChambostHClaeyssens-DonadelSRecombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia ABlood2014124233398340825253771
   PubMed Web of Science ®Google Scholar
• BorelYInduction of immunologic tolerance by a hapten (DNP) bound to a non-immunogenic carrierNat New Biol1971230141804928923
   PubMedGoogle Scholar
• GroomesCLGianferanteDMCrouchGDParekhDSScottDWLieuwKReduction of factor VIII inhibitor titers during immune tolerance induction with recombinant factor VIII-Fc fusion proteinPediatr Blood Cancer201663592292426739399
   PubMed Web of Science ®Google Scholar
• MalecLMJourneycakeJRagniMVExtended half-life factor VIII for immune tolerance induction in haemophiliaHaemophilia2016226e552e55427640873
   PubMed Web of Science ®Google Scholar
• IorioAPuccettiPMakrisMClotting factor concentrate switching and inhibitor development in hemophilia ABlood2012120472072722692511
   PubMed Web of Science ®Google Scholar
• IngMGuptaNTeyssandierMImmunogenicity of long-lasting recombinant factor VIII productsCell Immunol2016301404826723503
   PubMed Web of Science ®Google Scholar
• HasanHShaikhOMRassekhSRHowardAFGoddardKComparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: a meta-analysis and systematic reviewPediatr Blood Cancer2016641818827578304
   PubMed Web of Science ®Google Scholar
• KrishnamoorthySLiuTDragerDRecombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A miceCell Immunol2015301303926775174
   PubMed Web of Science ®Google Scholar
• PeyvandiFMannucciPMGaragiolaIA randomized trial of factor VIII and neutralizing antibodies in hemophilia AN Engl J Med2016374212054206427223147
   PubMed Web of Science ®Google Scholar
• EttingshausenCEKreuzWRecombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor developmentHaemophilia200612suppl 6102106
   PubMed Web of Science ®Google Scholar
• MASACMASAC Recommendation on SIPPET (Survey of Inhibitors in Plasma-Product-Exposed Toddlers): REsults and Recommendations for Treatment Products for Previously Untreated Patients with Hemophilia AMASAC2016
   Google Scholar
• ShimaMHanabusaHTakiMFactor VIII-mimetic function of humanized bispecific antibody in hemophilia AN Engl J Med2016374212044205327223146
   PubMed Web of Science ®Google Scholar
• DragerDPatarroyo-WhiteSChaoHRecombinant FVIIIFc-VWF-XTEN demonstrates significant bioavailability following subcutaneous administration in hemophilia A miceBlood20151263492
   Web of Science ®Google Scholar
• NathwaniACReissUMTuddenhamEGLong-term safety and efficacy of factor IX gene therapy in hemophilia BN Engl J Med2014371211994200425409372
   PubMed Web of Science ®Google Scholar